TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This study will provide a rationale for switch from lamivudine plus adefovir to tenofovir
monotherapy in Lamivudine plus Adefovir Treated Lamivudine-resistant chronic hepatitis B
patients with Undetectable Hepatitis B Virus DNA
Phase:
Phase 4
Details
Lead Sponsor:
Keimyung University Dongsan Medical Center
Collaborators:
Daegu Catholic University Medical Center DongGuk University Kyungpook National University Kyungpook National University Hospital Pusan National University Hospital Yeungnam University Yeungnam University Hospital